To include your compound in the COVID-19 Resource Center, submit it here.

Seeking domestic partners

How the syndicate behind TCR2’s $125M series B could aid development in China

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China.

6 Dimensions Capital and Curative Ventures led the untranched round. China-focused investors Hillhouse Capital, Syno Capital, Haitong International Securities

Read the full 464 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE